Received a "Study May Proceed” letter from the FDA for the Phase 2 trial for the treatment of FAP. This trial, run by CP-CTNet and financially supported by the NCI's Division of Cancer Prevention, ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China ...

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). The FDA also approved ...